| Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (NCT05451784) | Fundacio Clinic Barcelona | 2022-07-20 |
| Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer (NCT04634747) | OncoPep, Inc. | 2022-04-30 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer (NCT05081492) | City of Hope Medical Center | 2021-10-18 |
| Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (NCT04639245) | Fred Hutchinson Cancer Center | 2021-07-19 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (NCT03606967) | National Cancer Institute (NCI) | 2021-04-13 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (NCT04345913) | National Cancer Institute (NCI) | 2021-03-01 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC (NCT04664829) | National Cancer Centre, Singapore | 2020-10-01 |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (NCT04445844) | Mridula George, MD | 2020-07-13 |
| Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT04249167) | Mayo Clinic | 2020-01-23 |
| Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (NCT03941730) | Mayo Clinic | 2019-08-28 |
| Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer (NCT03853707) | City of Hope Medical Center | 2019-03-04 |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (NCT03589339) | Nanobiotix | 2019-01-16 |
| AMTEC IIT: Phase 2 Multiarm Study in TNBC (NCT03801369) | Gordon Mills, MD, PhD | 2018-12-12 |
| M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (NCT03579472) | M.D. Anderson Cancer Center | 2018-05-30 |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT03106415) | Mayo Clinic | 2017-09-27 |
| Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (NCT02971761) | City of Hope Medical Center | 2017-06-01 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
| Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases (NCT02595905) | National Cancer Institute (NCI) | 2016-09-15 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613) | National Cancer Institute (NCI) | 2016-08-31 |
| A Compassionate Use Study of Leronlimab in Breast Cancer (NCT04313075) | CytoDyn, Inc. | |
| Expanded Access for IMMU-132 (NCT04320693) | Gilead Sciences | |